SAILONG Pharmaceutical Group's wholly-owned subsidiary, Hunan SAILONG Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of the chemical raw material drug pemetrexed disodium. The approval notice is valid until May 27, 2031. This development will enhance the company's raw material drug product pipeline, although production and sales remain subject to various uncertainties.
Summary generated by AI · Always verify with source document
Securities Code: 002898
Securities Abbreviation: *ST SAILONG
Announcement Number: 2026-060
SAILONG Pharmaceutical Group Co., Ltd. announces that its wholly-owned subsidiary, Hunan SAILONG Pharmaceutical Co., Ltd., has recently received the approval notice for the listing application of the chemical raw material drug pemetrexed disodium issued by the National Medical Products Administration. The relevant information is announced as follows:
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.